Company Analysis Apogee Therapeutics, Inc. Common Stock
1. Summary
Advantages
- Price (77.32 $) is less than fair price (88.67 $)
- The stock's return over the last year (143.14%) is higher than the sector average (-2.93%).
Disadvantages
- Dividends (0%) are below the sector average (0.544%).
- Current debt level 1.57% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-33.22%) is lower than the sector average (ROE=109.03%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Apogee Therapeutics, Inc. Common Stock | Healthcare | Index | |
|---|---|---|---|
| 7 days | -1% | -13.4% | -0.6% |
| 90 days | 45% | -1.6% | 2.9% |
| 1 year | 143.1% | -2.9% | 21% |
APGE vs Sector: Apogee Therapeutics, Inc. Common Stock has outperformed the "Healthcare" sector by 146.08% over the past year.
APGE vs Market: Apogee Therapeutics, Inc. Common Stock has outperformed the market by 122.16% over the past year.
Stable price: APGE is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: APGE with weekly volatility of 2.75% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (77.32 $) is lower than the fair price (88.67 $).
Price not significantly lower than the fair price: The current price (77.32 $) is slightly lower than the fair price by 14.7%.
5.2. P/E
P/E vs Sector: The company's P/E (-11.3) is higher than that of the sector as a whole (-205.4).
P/E vs Market: The company's P/E (-11.3) is higher than that of the market as a whole (-65.33).
5.3. P/BV
P/BV vs Sector: The company's P/BV (3.49) is lower than that of the sector as a whole (245).
P/BV vs Market: The company's P/BV (3.49) is lower than that of the market as a whole (50.62).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (61.67).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (138.73).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-10.93) is lower than that of the sector as a whole (12.25).
EV/Ebitda vs Market: The company's EV/Ebitda (-10.93) is higher than that of the market as a whole (-48.34).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by 0% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (0%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-609.67%).
6.4. ROE
ROE vs Sector: The company's ROE (-33.22%) is lower than that of the sector as a whole (109.03%).
ROE vs Market: The company's ROE (-33.22%) is lower than that of the market as a whole (-10.16%).
6.6. ROA
ROA vs Sector: The company's ROA (-31.53%) is lower than that of the sector as a whole (-2.42%).
ROA vs Market: The company's ROA (-31.53%) is lower than that of the market as a whole (40.05%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0.8343%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (8.78%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.544%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
